1-甲氧基-4-溴-2-萘甲酸甲酯 | 5813-38-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 1-甲氧基-4-溴-2-萘甲酸甲酯
• 英文名称: methyl 1-methoxy-4-bromo-2-naphthoate
• 英文别名: methyl 4-bromo-1-methoxy-2-naphthoate；4-bromo-1-methoxy-[2]naphthoic acid methyl ester；4-Brom-1-methoxy-[2]naphthoesaeure-methylester；1-methoxy-4-bromo-2-naphthoic acid methyl ester；4-bromo-1-methoxy-2-naphthoate；1-Methoxy-4-brom-2-naphthoesaeure-methylester；methyl 4-bromo-1-methoxynaphthalene-2-carboxylate
• CAS: 5813-38-7
• 化学式: C₁₃H₁₁BrO₃
• 分子量: 295.133
• InChiKey: KXAZHBLGELHTTR-UHFFFAOYSA-N

物化性质

• 熔点：
  94 °C
• 沸点：
  397.0±22.0 °C(Predicted)
• 密度：
  1.463±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-甲氧基-4-溴-2-萘甲酸甲酯 在 sodium hydroxide 、 氯化亚砜 作用下， 以 甲醇 、 水 、 苯 为溶剂， 反应 3.0h， 生成 4-Brom-1-methoxynaphthalin-2-carbonsaeurechlorid
  参考文献：
  名称：

  Mach, Robert H.; Hammond, Philip S.; Huang, Yunsheng, Medicinal Chemistry Research, 1999, vol. 9, # 6, p. 355 - 373

  摘要：

  DOI：
• 作为产物：
  描述：

  1-羟基-2-萘甲酸 在 溴 、 potassium carbonate 作用下， 以 溶剂黄146 、 丙酮 为溶剂， 反应 86.0h， 生成 1-甲氧基-4-溴-2-萘甲酸甲酯
  参考文献：
  名称：

  [EN] NAPHTHALENE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
  [FR] COMPOSÉS DE NAPHTHALÈNE CARBOXAMIDE, MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR M1

  摘要：

  本发明涉及式(I)的萘甲酰胺化合物，它们是M1受体阳性变构调节剂，可用于治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。该发明还涉及包含这些化合物的药物组合物，以及在治疗由M1受体介导的疾病中使用这些化合物和组合物。

  公开号：

  WO2011149801A1

文献信息

• NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
  申请人：Lee Jinhwa

  公开号：US20120101051A1

  公开（公告）日：2012-04-26

  A novel C-aryl glucoside compound, or a pharmaceutically acceptable salt or a prodrug thereof having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney; and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly, diabetes, are provided.

  提供了一种新型的C-芳基葡萄糖苷化合物，或其药学上可接受的盐或前药，具有抑制肠道和肾脏中存在的钠依赖性葡萄糖共转运体2（SGLT2）的活性；以及包含该化合物作为活性成分的制药组合物，可用于预防或治疗代谢性疾病，特别是糖尿病。
• NAPHTHALENE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
  申请人：Beshore Douglas C.

  公开号：US20130059860A1

  公开（公告）日：2013-03-07

  The present invention is directed to naphthalene carboxamide compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimers disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及公式（I）的萘甲酰胺化合物，其为M1受体正向变构调节剂，并且可用于治疗与M1受体有关的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。本发明还涉及包含该化合物的制药组合物以及使用该化合物和组合物治疗M1受体介导的疾病。
• Thiazole derivatives as SGLT2 inhibitors and pharmaceutical composition comprising same
  申请人：Lee Jinhwa

  公开号：US08586550B2

  公开（公告）日：2013-11-19

  The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes.

  本发明涉及一种新型含噻唑环的化合物，具有对存在于肠和肾中的钠依赖性葡萄糖协同转运体2（SGLT2）的抑制活性，以及包含该化合物作为活性成分的药物组合物，可用于预防或治疗代谢性疾病，特别是糖尿病。
• Naphthalene carboxamide M1 receptor positive allosteric modulators
  申请人：Beshore Douglas C.

  公开号：US08883850B2

  公开（公告）日：2014-11-11

  The present invention is directed to naphthalene carboxamide compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimers disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及公式（I）的萘甲酰胺化合物，它们是M1受体正向变构调节剂，并且在治疗M1受体参与的疾病，例如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍方面有用。本发明还涉及包括该化合物的制药组合物以及使用该化合物和组合物治疗M1受体介导的疾病。
• Thiazole Derivatives as SGLT2 Inhibitors and Pharmaceutical Composition Comprising Same
  申请人：Lee Jinhwa

  公开号：US20130090298A1

  公开（公告）日：2013-04-11

  The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes.

  本发明涉及一种新型含有噻唑环的化合物，具有对存在于肠和肾中的钠依赖性葡萄糖共转运体2（SGLT2）的抑制活性，以及包含该化合物作为活性成分的制药组合物，用于预防或治疗代谢性疾病，特别是糖尿病。